Search research articles
Contact Us
Filters
Showing results (71-80 of 87) with videos related to
Page
of 9
Sort By:
Journal of Hepatology
|
September 16, 2003
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C
Gerlinde Teuber, M Pascu, T Berg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
Arthritis and Rheumatism
|
November 11, 1999
Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis
M M Maurice, H Nakamura, S Gringhuis, et al.
British Journal of Cancer
|
December 11, 2008
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
G Huebner, H Link, C H Kohne, et al.
British Journal of Cancer
|
January 19, 2013
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
A Atmaca, S-E Al-Batran, D Werner, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
ESMO Open
|
May 4, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 87) with videos related to
Sort By:
Page
of 9
Journal of Hepatology
|
September 16, 2003
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C
Gerlinde Teuber, M Pascu, T Berg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 9, 2020
Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306)
J W Holch, S Held, S Stintzing, et al.
Arthritis and Rheumatism
|
November 11, 1999
Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis
M M Maurice, H Nakamura, S Gringhuis, et al.
British Journal of Cancer
|
December 11, 2008
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial
G Huebner, H Link, C H Kohne, et al.
British Journal of Cancer
|
January 19, 2013
A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
A Atmaca, S-E Al-Batran, D Werner, et al.
ESMO Gastrointestinal Oncology
|
April 17, 2026
Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP trial (AIO-PAK-0113)
B Kimmel, S T Löhnert, F Wedekink, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 18, 2018
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'
M Haas, J T Siveke, M Schenk, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 30, 2018
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)
J W Holch, I Ricard, S Stintzing, et al.
ESMO Open
|
May 4, 2024
Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552]
I Hartlapp, D Valta-Seufzer, J T Siveke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 3, 2017
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S Stintzing, L Miller-Phillips, D P Modest, et al.
Page
of 9